Other drugs may interact with metronidazole, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor if you are pregnant or if you become pregnant while using this medicine.To make sure metronidazole is safe for you, tell your doctor if you have ever had:a stomach or intestinal disease such as Crohn's disease;a blood cell disorder such as anemia (lack of red blood cells) or low white blood cell (WBC) counts;In animal studies, metronidazole caused certain types of tumors, some of which were cancerous. Call your doctor for medical advice about side effects. If the administration of Metronidazole cannot be separated from the dialysis session, supplementation of Metronidazole dose following hemodialysis should be considered (see Following a single intravenous infusion of 500 mg Metronidazole, the mean AUC24 of Metronidazole was higher by 114% in patients with severe (Child-Pugh C) hepatic impairment, and by 54% and 53% in patients with mild (Child-Pugh A) and moderate (Child-Pugh B) hepatic impairment, respectively, compared to healthy control subjects. Fertility was restored in most rats after an eight week, drug-free recovery period.There are no adequate and well controlled studies of Metronidazole tablets, USP in pregnant women. Alternatively, a nursing mother may choose to pump and discard human milk for the duration of Metronidazole therapy, and for 24 hours after therapy ends and feed her infant stored human milk or formula.In elderly geriatric patients, monitoring for Metronidazole associated adverse events is recommended (see Safety and effectiveness in pediatric patients have not been established, except for the treatment of amebiasis.The following reactions have been reported during treatment with Metronidazole:Patients with Crohn’s disease are known to have an increased incidence of gastrointestinal and certain extraintestinal cancers. A maximum of 4 g should not be exceeded during a 24-hour period.The usual duration of therapy is 7 to 10 days; however, infections of the bone and joint, lower respiratory tract, and endocardium may require longer treatment.For patients with severe hepatic impairment (Child-Pugh C), the dose of Metronidazole tablets, USP should be reduced by 50% (see Hemodialysis removes significant amounts of Metronidazole and its metabolites from systemic circulation. Most BE studies that were identified reported the investigated formulations to be bioequivalent, indicating the risk of bioinequivalence to be low. The elimination half-life, measured during the first 3 days of life, was inversely related to gestational age. Der Wirkstoff schmeckt bitter, weshalb Tabletten vor der oralen Eingabe nicht zerd… Oral administration of 250 mg, 500 mg, or 2,000 mg produced peak plasma concentrations of 6 mcg/mL, 12 mcg/mL, and 40 mcg/mL, respectively. Both the parent compound and the hydroxyl metabolite possess Renal clearance of Metronidazole is approximately 10 mL/min/1.73 m Decreased renal function does not alter the single-dose pharmacokinetics of Metronidazole.Following a single intravenous infusion or oral dose of Metronidazole 500 mg, the clearance of Metronidazole was investigated in ESRD subjects undergoing hemodialysis or continuous ambulatory peritoneal dialysis (CAPD). Inactive ingredients include colloidal silicon dioxide, crospovidone, magnesium stearate, microcrystalline cellulose, and stearic acid.Disposition of Metronidazole in the body is similar for both oral and intravenous dosage forms. Discontinue consumption of alcohol or products containing propylene glycol during and for at least three days after therapy with Metronidazole (see Encephalopathy and peripheral neuropathy: Cases of encephalopathy and peripheral neuropathy (including optic neuropathy) have been reported with Metronidazole.Encephalopathy has been reported in association with cerebellar toxicity characterized by ataxia, dizziness, and dysarthria. Symptoms can occur within hours of dose administration and generally resolve after Metronidazole therapy is discontinued.The appearance of abnormal neurologic signs and symptoms demands the prompt evaluation of the benefit/risk ratio of the continuation of therapy (see Cases of severe hepatotoxicity/acute hepatic failure, including cases with a fatal outcome with very rapid onset after treatment initiation in patients with Cockayne syndrome have been reported with products containing Metronidazole for systemic use. Let your doctor know if you are breastfeeding prior to taking metronidazole.Do not give this medicine to a child without medical advice.Take metronidazole exactly as prescribed by your doctor. Because of the potential for tumorigenicity shown for Metronidazole in mouse and rat studies, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.